PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review
No Thumbnail Available
Date
2014-05-01